Navigation Links
La Jolla Institute continues longtime collaboration with Kyowa Hakko Kirin California
Date:7/30/2013

SAN DIEGO (July 30, 2013) La Jolla Institute for Allergy and Immunology and Kyowa Hakko Kirin California, Inc. (KKC), a wholly-owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (KHK) , a global specialty pharmaceutical company, today announced the signing of a new agreement that marks another milestone in one of the most enduring industry-academic collaborations in the world.

The six-year agreement continues a research alliance spanning more than two decades between La Jolla Institute, an academic nonprofit and a world leader in immunology research, and KKC, one of Kyowa Hakko Kirin's research and development centers in the United States. The collaboration leverages the pharmaceutical company's discovery and development capabilities and La Jolla Institute's expertise in basic research to accelerate translation of research discoveries into potential new treatments.

Under the terms of the agreement, La Jolla Institute will receive a combination of discretionary research funding, and funds dedicated to specific projects to be selected by a steering committee of La Jolla Institute and Kyowa Hakko Kirin leaders. The research funding agreement will span through the end of 2018. Kyowa Hakko Kirin California will receive first rights of negotiation to pursue translation of La Jolla Institute discoveries, stemming from research projects funded by KKC.

La Jolla Institute Chief Business Officer Patrick Ho says the agreement is a win-win for both parties. "La Jolla Institute benefits from the added funding to support research that may eventually make its way into KHK's pharmaceutical research and development pipeline," says Ho. "No doubt this collaboration is exceptional and stands apart among the Institute's agreements with pharmaceutical companies."

Mitchell Kronenberg, Ph.D., La Jolla Institute president & chief scientific officer, says the contract "continues the long tradition of scientific excellence and mutual respect that has existed between our two organizations for the last 25 years."

Hiroshi Yano, Ph.D., the newly-appointed KKC president, says the agreement will further enhance the longstanding relationship. "While the investment efficiency of drug discovery and development is challenging for the pharmaceutical industry, this new agreement enables closer collaboration that will allow KKC and the La Jolla Institute to greatly enhance target identification and drug discovery efforts," says Dr. Yano. He notes that the new agreement structure, involving a joint steering committee for project selection, is "only achievable based on our mutual understanding and history. I appreciate the culture built by our predecessors."

La Jolla Institute Board Member David Webb, Ph.D., a scientist and biotech industry veteran, notes that the partnership is beneficial for everyone involved, most importantly for the millions of people worldwide who are desperately in need of new and better treatments for disease. "Collaborations between research centers like La Jolla Institute and pharmaceutical companies such as KHK create a bridge that propels major discoveries from the laboratory into drug development and ultimately into the hands of people suffering from disease," says Dr. Webb, chairman emeritus of Biocom, the San Diego-based life science industry trade association.

Dr. Yano expects new synergies to be created between KKC and the La Jolla Institute. "We have already seen that the science of the La Jolla Institute is advancing drug discovery in KKC, and I hope that KKC's drug discovery expertise will also help foster continued scientific breakthroughs at the Institute. My hope is that this virtuous cycle leads to improved human health worldwide."

Reflecting this goal, several La Jolla Institute discoveries are advancing toward becoming new treatments for debilitating disorders including psoriasis, inflammatory bowel disease and rheumatoid arthritis, thanks to the partnership. Several of these potential therapies, including a drug that eases immune rejection problems in patients following organ transplantation, are in phase II clinical human studies, with others at various stages of development.

Dr. Kronenberg notes that academic-industry relationships are critical to advance the true mission of nonprofit academic research institutes. "Our ultimate goal is to see our findings put into direct use for improving human health," he notes. "It's the reason we exist." However, most research institutes aren't equipped for clinical trials and other aspects of drug development, which underscores the need for relationships between research nonprofits and pharmaceutical companies.

"KHK has the kind of long-term commitment that is necessary to take discoveries from the bench, into human clinical studies, and, if successful, into approved drugs," he says. "It's a complementary process without which many important breakthroughs might never get beyond the laboratory stage."

While research agreements between academic institutions and pharmaceutical companies are commonplace today, the collaboration between KKC and La Jolla Institute dates back to the Institute's founding in 1988, at a time when such arrangements were quite rare. "Our institute was fortunate to have been founded by a group of individuals with incredible vision and foresight about the necessity for strong linkages between academia and the pharmaceutical industry," says Dr. Kronenberg. "Back then it was a very novel even controversial idea."

"Their wisdom has proven extremely accurate," he adds. "Today such arrangements are a pivotal piece of drug discovery efforts throughout this country."


'/>"/>

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology
Source:Eurekalert

Related biology news :

1. La Jolla Institute discovery could lead to new way to screen drugs for adverse reactions
2. La Jolla Institute scientist discovers key step in immune system-fueled inflammation
3. La Jolla institute identifies critical cell in fighting E. coli infection
4. La Jolla Institute identifies molecular switch enabling immune cells to better fight disease
5. La Jolla Institute discovers new player critical to unleashing T cells against disease
6. Diabetes Research Institute develops oxygen-generating biomaterial
7. Space research institute honors Sen. Hutchison with Pioneer Award
8. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
9. Minneapolis Heart Institute selected to participate in Cardiovascular Cell Therapy Research Network
10. Cary Institute Hydrofracking Forum
11. Scripps Research Institute Professor Gerald F. Joyce elected to American Academy of Arts & Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back ... 8th June 2018 in San Francisco, CA. The Summit brings together current and former ... CEOs, board directors and government officials from around the world to address key issues ...
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... ... , ... Disappearing forests and increased emissions are the main causes of the ... Especially those living in larger cities are affected by air pollution related diseases. , ... pollution-affected countries globally - decided to take action. , “I knew I had to ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
Breaking Biology Technology: